Biodexa Pharmaceuticals (BDRX) Competitors $6.91 -0.08 (-1.14%) Closing price 08/13/2025 03:59 PM EasternExtended Trading$6.79 -0.12 (-1.74%) As of 05:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock BDRX vs. ZNTL, HLVX, CRBP, ADAG, PLRX, COYA, ATOS, HURA, ANEB, and MGNXShould you be buying Biodexa Pharmaceuticals stock or one of its competitors? The main competitors of Biodexa Pharmaceuticals include Zentalis Pharmaceuticals (ZNTL), HilleVax (HLVX), Corbus Pharmaceuticals (CRBP), Adagene (ADAG), Pliant Therapeutics (PLRX), Coya Therapeutics (COYA), Atossa Genetics (ATOS), TuHURA Biosciences (HURA), Anebulo Pharmaceuticals (ANEB), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical products" industry. Biodexa Pharmaceuticals vs. Its Competitors Zentalis Pharmaceuticals HilleVax Corbus Pharmaceuticals Adagene Pliant Therapeutics Coya Therapeutics Atossa Genetics TuHURA Biosciences Anebulo Pharmaceuticals MacroGenics Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment. Which has more risk and volatility, ZNTL or BDRX? Zentalis Pharmaceuticals has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Comparatively, Biodexa Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Do analysts prefer ZNTL or BDRX? Zentalis Pharmaceuticals currently has a consensus price target of $8.20, suggesting a potential upside of 450.34%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Zentalis Pharmaceuticals is more favorable than Biodexa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zentalis Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.67Biodexa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders have more ownership in ZNTL or BDRX? 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 1.9% of Zentalis Pharmaceuticals shares are held by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to ZNTL or BDRX? In the previous week, Zentalis Pharmaceuticals had 19 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 20 mentions for Zentalis Pharmaceuticals and 1 mentions for Biodexa Pharmaceuticals. Biodexa Pharmaceuticals' average media sentiment score of 1.42 beat Zentalis Pharmaceuticals' score of 0.71 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Zentalis Pharmaceuticals Positive Biodexa Pharmaceuticals Positive Which has higher earnings & valuation, ZNTL or BDRX? Biodexa Pharmaceuticals has lower revenue, but higher earnings than Zentalis Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZentalis Pharmaceuticals$26.87M4.00-$165.84M-$2.26-0.66Biodexa PharmaceuticalsN/AN/A-$7.32MN/AN/A Is ZNTL or BDRX more profitable? Biodexa Pharmaceuticals' return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Zentalis PharmaceuticalsN/A -51.62% -40.28% Biodexa Pharmaceuticals N/A N/A N/A SummaryZentalis Pharmaceuticals beats Biodexa Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDRX vs. The Competition Export to ExcelMetricBiodexa PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.54M$3.03B$5.54B$9.82BDividend YieldN/A2.27%4.62%4.11%P/E RatioN/A20.6730.1526.03Price / SalesN/A363.56461.34104.73Price / CashN/A42.0537.7558.93Price / Book2.377.638.496.06Net Income-$7.32M-$54.65M$3.26B$265.11M7 Day Performance1.62%5.41%4.19%3.38%1 Month Performance-29.49%7.14%4.64%2.28%1 Year PerformanceN/A31.27%35.15%29.67% Biodexa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDRXBiodexa Pharmaceuticals0.2009 of 5 stars$6.91-1.1%N/AN/A$25.54MN/A0.0020Positive NewsZNTLZentalis Pharmaceuticals2.312 of 5 stars$1.40-2.8%$8.20+485.7%-50.8%$103.88M$67.43M-0.62160Analyst RevisionHLVXHilleVax1.8131 of 5 stars$2.06-0.5%$2.00-2.9%+21.1%$103.54MN/A-1.4420CRBPCorbus Pharmaceuticals4.3241 of 5 stars$8.67+2.8%$49.00+465.2%-81.9%$103.31MN/A-1.8240ADAGAdagene2.9751 of 5 stars$2.29+5.5%$7.50+227.5%-32.7%$102.23M$100K0.00260Gap UpPLRXPliant Therapeutics4.0511 of 5 stars$1.70+2.4%$8.19+381.6%-87.0%$101.90M$1.58M-0.5090Earnings ReportCOYACoya Therapeutics2.0473 of 5 stars$6.15+1.2%$16.50+168.3%+20.6%$101.69M$3.55M-5.756Trending NewsEarnings ReportAnalyst ForecastATOSAtossa Genetics2.401 of 5 stars$0.76-3.0%$6.17+707.9%-39.5%$101.66MN/A-3.638News CoverageEarnings ReportHURATuHURA Biosciences1.8108 of 5 stars$3.05+32.6%$12.67+315.3%N/A$100.46MN/A0.00N/ANews CoverageHigh Trading VolumeANEBAnebulo Pharmaceuticals2.2286 of 5 stars$2.37-1.7%$5.50+132.1%+29.7%$98.90MN/A-9.124MGNXMacroGenics4.5916 of 5 stars$1.47-4.5%$5.40+267.3%-53.0%$97.16M$149.96M-1.65430Positive NewsUpcoming Earnings Related Companies and Tools Related Companies Zentalis Pharmaceuticals Competitors HilleVax Competitors Corbus Pharmaceuticals Competitors Adagene Competitors Pliant Therapeutics Competitors Coya Therapeutics Competitors Atossa Genetics Competitors TuHURA Biosciences Competitors Anebulo Pharmaceuticals Competitors MacroGenics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BDRX) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGet This Stock NowThis company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardwa...InvestorPlace | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredD.C.’s secret plan to crush the debt.At a recent gathering with some of the most powerful people in America, Jeff discovered the Trump administrati...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals PLC Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access